BlueCrest Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

BlueCrest Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,785	Closed	-$472K	–	605
2019 Q3	$472K	Buy	+2,785	New	+$493K	0.03%	276
2018 Q4	–	Sell	-1,836	Closed	-$354K	–	1439
2018 Q3	$354K	Sell	1,836 -5,662	-76%	-$1.01M	0.01%	946
2018 Q2	$1.27M	Buy	+7,498	New	+$1.16M	0.03%	447
2018 Q1	–	Sell	-63,000	Closed	-$9.44M	–	1646
2017 Q4	$9.44M	Buy	+63,000	New	+$9.33M	0.26%	81
2017 Q2	–	Sell	-3,231	Closed	-$353K	–	1120
2017 Q1	$353K	Buy	+3,231	New	+$284K	0.02%	497
2016 Q1	–	Sell	-3,851	Closed	-$485K	–	1126
2015 Q4	$485K	Buy	3,851 +1,618	+72%	+$195K	0.02%	592
2015 Q3	$233K	Buy	+2,233	New	+$287K	0.01%	768

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlueCrest Capital Management's VRTX Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2019, closing a stake of 2,785 shares — an estimated $472K sold.

BlueCrest Capital Management first reported a position in VRTX in Q3 2015 and held it in 7 quarters. The position peaked at $9.44M in Q4 2017. 813 funds tracked by Wall St. Rank hold VRTX as of Q4 2019.

BlueCrest Capital Management reported no remaining Vertex Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
BlueCrest Capital Management sold 2,785 Vertex Pharmaceuticals shares in Q4 2019, an estimated $472K.
BlueCrest Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2015 and held it in 7 quarters.
BlueCrest Capital Management's Vertex Pharmaceuticals position peaked at $9.44M in Q4 2017.
813 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.